http://www.ewg.org/reports/skindeep/report/impurities.php
Breast cancer and impurities. EWG's assessment of product
ingredient labels and data on cancer-causing chemicals identified
three common impurities in personal care products that are linked to
mammary tumors in animal studies — ethylene oxide, PAHs, and
1,3-butadiene.
The ingredients for which these impurities are of concern are
used in one of every four personal care products on the market (Table
4).
Among girls born today, one in eight is expected to get breast
cancer and one in 30 is expected to die from it (NCI 1996, 1997,
2000). A review by scientists from Lawrence Berkeley National
Laboratory shows that as many as one of every five chemical
carcinogens causes mammary tumors in laboratory studies, indicating
that the breast is more sensitive to carcinogens than almost any
other tissue in the body (Gold et al. 1991). EWG's identification of
three impurities linked to breast cancer does not represent a full
accounting of possible mammary carcinogens in personal care
products. Instead, it is a partial accounting based on the National
Toxicology Program's assessment of mammary carcinogens (NTP 2000)
and other sources in the peer-reviewed literature. Further study
would likely identify additional ingredients in personal care
products that raise concerns with respect to breast cancer.
PAHs. PAHs, or polycyclic aromatic hydrocarbons, are
common contaminants in petrolatum, also called petroleum jelly and
sold under well-known brand names like Vaseline. Petrolatum
is found in one of every 14 products on the market (7.1 percent of
the products assessed by EWG), including 15 percent of all lipstick
and 40 percent of al baby lotions and oils. FDA restricts petrolatum
in food to no more than 10 parts per million, and requires
petrolatum used in food packaging or drugs to meet impurity
restrictions for PAHs (21 CFR 178, 21 CFR 172.880).
But the agency allows any amount of petrolatum of any purity
in personal care products, many of which are applied directly to the
lips and swallowed.
Manufacturers would find no legal impediments to using the
same unregulated petrolatum in personal care products as can be used
in shoe polish.
Among the studies linking the petrolatum impurity PAHs to breast
cancer is a Columbia University study in which researchers found
that the breast tissue of women with breast cancer was 2.6 times
more likely to contain elevated levels of PAHs bound to DNA (called
DNA adducts) than the breast tissue of women without breast cancer
(Rundle et al. 2000). The National Toxicology Programs finds that
some PAHs are reasonable anticipated to be human carcinogens, and
the State of California lists a number of PAHs as carcinogens in its
Proposition 65 program (NTP 2002, OEHHA 2004).
Petrolatum is listed as a probable human carcinogen in the
European Union's Dangerous Substances Directive (UNECE 2004),
and its use in cosmetics will be banned by September 2004 with the
following caveat:
“The classification as a carcinogen need not apply if the full
refining history is known and it can be shown that the substance
from which it is produced is not a carcinogen.”
Chemical industry sources have interpreted this clause to mean
that petrolatum will continue to be allowed in cosmetics in the EU
if it is refined and meets PAH purity standards for food set by FDA
(Faust and Casserly 2003). Even this purity standard does not set
direct limits on PAH content, but instead relies on a light
absorption test as an indirect indicator of contamination.
In the U.S. no requirement for refinement applies for petrolatum
in personal care products. Some manufacturers likely choose refined
petrolatum low in PAHs, but perhaps some do not.
Product labels do not uniformly show the “USP” certification
on the petrolatum listing in EWG's ingredient label database, and in
any event, the certification criteria for a USP listing are not
public.
Some product labels include the term “skin protectant” in
parentheses after the petrolatum listing, an indication that the
petrolatum has been refined and meets FDA requirements for drug
applications.
But in most cases a consumer buying a product containing
petrolatum has no way to know if the ingredient is low in
carcinogenic PAHs or not.
Read the full report on the EWA website.
CLICK HERE